|
US6469158B1
(en)
|
1992-05-14 |
2002-10-22 |
Ribozyme Pharmaceuticals, Incorporated |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
|
US5977343A
(en)
|
1992-05-14 |
1999-11-02 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
|
US5804683A
(en)
|
1992-05-14 |
1998-09-08 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA with alkylamine
|
|
ATE227342T1
(de)
|
1993-09-02 |
2002-11-15 |
Ribozyme Pharm Inc |
Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
|
|
US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
|
US5998203A
(en)
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
|
US6111086A
(en)
|
1998-02-27 |
2000-08-29 |
Scaringe; Stephen A. |
Orthoester protecting groups
|
|
ES2336887T5
(es)
|
2000-03-30 |
2019-03-06 |
Whitehead Inst Biomedical Res |
Mediadores de interferencia por ARN específicos de secuencias de ARN
|
|
CA2429814C
(en)
|
2000-12-01 |
2014-02-18 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
US20050159378A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
|
WO2003040395A2
(en)
|
2001-11-07 |
2003-05-15 |
Applera Corporation |
Universal nucleotides for nucleic acid analysis
|
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
WO2007030167A1
(en)
|
2005-09-02 |
2007-03-15 |
Nastech Pharmaceutical Company Inc. |
Modification of double-stranded ribonucleic acid molecules
|
|
DK2341943T3
(en)
|
2008-09-22 |
2019-02-25 |
Dicerna Pharmaceuticals Inc |
COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS
|
|
US8691971B2
(en)
|
2008-09-23 |
2014-04-08 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
KR101728655B1
(ko)
|
2008-12-18 |
2017-04-19 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
AU2012328680A1
(en)
|
2011-10-25 |
2014-05-01 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of GCCR expression
|
|
EP2928877B1
(en)
|
2012-12-06 |
2020-01-22 |
Merck Sharp & Dohme Corp. |
Disulfide masked prodrug compositions and methods
|
|
CA2950960A1
(en)
|
2014-06-06 |
2015-12-10 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having bioreversible and non-bioreversible groups
|
|
DK3569711T3
(da)
|
2014-12-15 |
2021-02-22 |
Dicerna Pharmaceuticals Inc |
Ligandmodificerede dobbeltstrengede nukleinsyrer
|
|
EP3387129A1
(en)
*
|
2015-12-10 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
JP7249080B2
(ja)
|
2016-08-23 |
2023-03-30 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用
|
|
HUE059718T2
(hu)
|
2016-09-02 |
2022-12-28 |
Dicerna Pharmaceuticals Inc |
4'-foszfát analógok és azokat tartalmazó oligonukleotidok
|
|
WO2020123083A1
(en)
*
|
2018-12-12 |
2020-06-18 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules containing a triloop
|
|
CA3141902A1
(en)
*
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Rnai constructs for inhibiting scap expression and methods of use thereof
|
|
MX2022008738A
(es)
*
|
2020-01-15 |
2022-09-23 |
Dicerna Pharmaceuticals Inc |
Acidos nucleicos de fosfonato de 4'-o-metileno y analogos de estos.
|
|
US20230287425A1
(en)
*
|
2020-03-18 |
2023-09-14 |
Dicerna Pharmacuticals Inc. |
Compositions and methods for inhibiting angptl3 expression
|
|
US12435336B2
(en)
*
|
2020-08-05 |
2025-10-07 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting LPA expression
|
|
EP4225919A1
(en)
*
|
2020-10-08 |
2023-08-16 |
Dicerna Pharmaceuticals, Inc. |
Selective delivery of oligonucleotides to glial cells
|